

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Merkel Cell Carcinoma

Version 1.2018 — September 18, 2017

NCCN.org

Continue

NCCN Guidelines Version 1.2018 Panel Members

Merkel Cell Carcinoma

*Christopher K. Bichakjian, MD/Chair ☒
University of Michigan
Comprehensive Cancer Center

Thomas Olencki, DO/Vice-Chair †
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Sumaira Z. Aasi, MD ☒
Stanford Cancer Institute

Murad Alam, MD ☒ ¶ ζ
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

James S. Andersen, MD ¶ Ÿ
City of Hope
Comprehensive Cancer Center

Rachel Blitzblau, MD, PhD §
Duke Cancer Center

Glen M. Bowen, MD ☒
Huntsman Cancer Institute
at the University of Utah

Carlo M. Contreras, MD ¶
University of Alabama at Birmingham
Comprehensive Cancer Center

Gregory A. Daniels, MD, PhD † ≠ Þ
UC San Diego Moores Cancer Center

Roy Decker, MD, PhD §
Yale Cancer Center/
Smilow Cancer Hospital

Jeffrey M. Farma, MD ¶
Fox Chase Cancer Center

Kris Fisher, MD ☒ ≠
St. Jude Children's Research Hospital/
University of Tennessee Health Science Center

Brian Gastman, MD Ÿ
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center and
Cleveland Clinic Taussig Cancer Institute

Karthik Ghosh, MD Þ
Mayo Clinic Cancer Center

Roy C. Grekin, MD ☒ ¶
UCSF Helen Diller Family
Comprehensive Cancer Center

Kenneth Grossman, MD, PhD †
Huntsman Cancer Institute at
the University of Utah

Alan L. Ho, MD, PhD †
Memorial Sloan Kettering Cancer Center

Karl D. Lewis, MD †
University of Colorado Cancer Center

Manisha Loss, MD ☒
Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Daniel D. Lydiatt, DDS, MD ¶
Fred & Pamela Buffett Cancer Center

Jane Messina, MD ≠
Moffitt Cancer Center

Kishwer S. Nehal, MD ☒ ¶
Memorial Sloan Kettering Cancer Center

Paul Nghiem, MD, PhD ☒
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance

Igor Puzanov, MD ‡
Roswell Park Cancer Institute

Chrysalynne D. Schmults, MD ☒ ¶
Dana-Farber/Brigham and Women's
Cancer Center | Massachusetts General
Hospital Cancer Center

Ashok R. Shaha, MD ¶ ζ
Memorial Sloan Kettering Cancer Center

Valencia Thomas, MD ☒
The University of Texas
MD Anderson Cancer Center

Yaohui G. Xu, MD, PhD ☒
University of Wisconsin
Carbone Cancer Center

John A. Zic, MD ☒
Vanderbilt-Ingram Cancer Center

☒ Dermatology
☐ Diagnostic/Interventional radiology
¶ Surgery/Surgical oncology
ζ Otolaryngology
≠ Pathology/Dermatopathology
† Medical oncology
Þ Internal medicine
§ Radiotherapy/Radiation oncology
Ÿ Reconstructive surgery
‡ Hematology/Hematology oncology
* Discussion Section Writing Committee

[NCCN Merkel Cell Carcinoma Panel Members](#) [Summary of the Guidelines Updates](#)

Merkel Cell Carcinoma

[Clinical Presentation, Preliminary Workup, Diagnosis, Additional Workup, and Clinical Findings \(MCC-1\)](#)

[Primary and Adjuvant Treatment of Clinical N0 Disease \(MCC-2\)](#)

[Primary and Adjuvant Treatment of Clinical N+ Disease \(MCC-3\)](#)

[Treatment of Clinical M1 Disease \(MCC-4\)](#)

[Follow-up and Recurrence \(MCC-5\)](#)

[Principles of Pathology \(MCC-A\)](#)

[Principles of Radiation Therapy \(MCC-B\)](#)

[Principles of Excision \(MCC-C\)](#)

[Principles of Systemic Therapy \(MCC-D\)](#)

[Staging \(ST-1\)](#)

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here](#): nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2017.



NCCN Guidelines Version 1.2018 Updates

Merkel Cell Carcinoma

Updates in Version 1.2018 of the NCCN Guidelines for Merkel Cell Carcinoma from Version 1.2017 include:

Merkel Cell Carcinoma

MCC-1

- Footnote "a" was amended: "~~The value of baseline MCPyV (Merkel cell polyomavirus) serology for prognostic significance and to track disease recurrence is being evaluated.~~ Quantitation of MCPyV oncoprotein antibodies may be considered as part of initial workup; sero-negative patients may have a higher risk of recurrence; in sero-positive patients, a rising titer may be an early indicator of recurrence." (Also for MCC-5)
- Footnote "c" was amended: "Brain MRI with contrast and neck/chest/abdomen/pelvis CT with contrast or *whole body* FDG PET/CT may be useful to identify and quantify regional and distant metastases. Some studies indicate that *whole body* FDG PET/CT may be preferred in some clinical circumstances. If *whole body* FDG PET/CT is not available, CT or MRI with contrast may be used. Imaging may also be useful to evaluate for the possibility of a skin metastasis from a noncutaneous primary neuroendocrine carcinoma (eg, small cell lung cancer), especially in cases where CK-20 is negative."

MCC-2

- Footnote "i" was amended: "Brain MRI with contrast and neck/chest/abdomen/pelvis CT with contrast or *whole body* FDG PET/CT may be useful to identify and quantify regional and distant metastases. Some studies indicate that *whole body* FDG PET/CT may be preferred in some clinical circumstances. If *whole body* FDG PET/CT is not available, CT or MRI with contrast may be used." (Also for MCC-5)

MCC-3

- Footnote "m" was amended: "Brain MRI with contrast and neck/chest/abdomen/pelvis CT with contrast or *whole body* FDG PET/CT ~~may be indicated~~ to evaluate extent of lymph node and/or visceral organ involvement. Some studies indicate that *whole body* FDG PET/CT may be preferred in some clinical circumstances. If *whole body* FDG PET/CT is not available, CT or MRI with contrast may be used."
- Footnote "n" was amended: "Adjuvant chemotherapy may be considered in select clinical circumstances; however, available retrospective studies do not suggest ~~prolonged~~ survival benefit for adjuvant chemotherapy. (See Principles of Systemic Therapy [MCC-D])."

MCC-D Principles of Systemic Therapy

- Local Disease
 - ▶ 1st bullet was amended: "Adjuvant chemotherapy not recommended ~~unless clinical judgement dictates otherwise~~"
- Under Regional Disease 1st bullet was added: "Clinical trial (preferred)"
- Under Disseminated Disease
 - ▶ Pembrolizumab was moved from under "as clinical judgment dicates."
 - ▶ Nivolumab (category 2A) and avelumab (category 2A) were added as systemic therapy options.
 - ▶ 4th bullet was amended: "As clinical judgement indicates *for patients with contraindications to checkpoint immunotherapy*"
- Footnote "2" was amended: "Preliminary data from non-randomized trials in patients with MCC demonstrate that ~~response rates for pembrolizumab are similar to those previously reported for chemotherapy~~ rates of durable response are improved with PD-1/PD-L1 blockade compared with cytotoxic therapy. The safety profiles for checkpoint immunotherapies are significantly different from cytotoxic therapies. Consult prescribing information for recommendations on detection and management of immune-related adverse events associated with checkpoint immunotherapies. Clinician and patient education is critical for safe administration of checkpoint immunotherapies."

ST-1 and ST-2 Staging Table


- The AJCC 8th Edition Cancer Staging System (2016) will be implemented on January 1, 2018.

UPDATES



NCCN Guidelines Version 1.2018

Merkel Cell Carcinoma



^aQuantitation of MCPyV oncoprotein antibodies may be considered as part of initial workup; sero-negative patients may have a higher risk of recurrence; in sero-positive patients, a rising titer may be an early indicator of recurrence.

^b[See Principles of Pathology \(MCC-A\)](#).

^cBrain MRI with contrast and neck/chest/abdomen/pelvis CT with contrast or whole body FDG PET/CT may be useful to identify and quantify regional and distant metastases. Some studies indicate that whole body FDG PET/CT may be preferred in some clinical circumstances. If whole body FDG PET/CT is not available, CT or MRI with contrast may be used. Imaging may also be useful to evaluate for the possibility of a skin metastasis from a noncutaneous primary neuroendocrine carcinoma (eg, small cell lung cancer), especially in cases where CK-20 is negative.

^dImaging is encouraged whenever metastatic or unresectable disease is suspected based on H&P findings. The most reliable staging tool to identify sub-clinical nodal disease is sentinel lymph node biopsy (SLNB).

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2018

Merkel Cell Carcinoma

PRIMARY AND ADJUVANT TREATMENT OF CLINICAL N0 DISEASE



^bSee Principles of Pathology (MCC-A).

^eSee Principles of Excision (MCC-C). In selected cases in which complete surgical excision is not possible, surgery is refused by the patient, or surgery would result in significant morbidity, radiation monotherapy may be considered (See Principles of Radiation Therapy [MCC-B]).

^fSurgical margins should be balanced with morbidity of surgery. If appropriate, avoid undue delay in proceeding to RT (See Principles of Excision MCC-C).

^gIn the head and neck region, risk of false-negative SLNBs is higher due to aberrant lymph node drainage and frequent presence of multiple SLN basins. If SLNB is not performed or is unsuccessful, consider irradiating nodal beds for subclinical disease (See Principles of Radiation Therapy MCC-B).

^hSLNB is an important staging tool for regional control, but the impact of SLNB on overall survival is unclear.

ⁱBrain MRI with contrast and neck/chest/abdomen/pelvis CT with contrast or whole body FDG PET/CT may be useful to identify and quantify regional and distant metastases. Some studies indicate that whole body FDG PET/CT may be preferred in some clinical circumstances. If whole body FDG PET/CT is not available, CT or MRI with contrast may be used.

^jSee Principles of Radiation Therapy (MCC-B).


^kConsider observation of the primary site in cases where the primary tumor is small (eg, <1 cm) and widely excised with no other adverse risk factors such as LVI (lymphovascular invasion) or immunosuppression.

^lConsider RT when there is a potential for anatomic [eg, previous history of surgery including WLE (wide local excision)], operator, or histologic failure (eg, failure to perform appropriate immunohistochemistry on SLNs) that may lead to a false-negative SLNB. Consider RT in cases of profound immunosuppression.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PRIMARY AND ADJUVANT TREATMENT OF CLINICAL N+ DISEASE



^bSee Principles of Pathology (MCC-A).

^mBrain MRI with contrast and neck/chest/abdomen/pelvis CT with contrast or whole body FDG PET/CT to evaluate extent of lymph node and/or visceral organ involvement. Some studies indicate that whole body FDG PET/CT may be preferred in some clinical circumstances. If whole body FDG PET/CT is not available, CT or MRI with contrast may be used.


^jSee Principles of Radiation Therapy (MCC-B).

ⁿAdjuvant chemotherapy may be considered in select clinical circumstances; however, available retrospective studies do not suggest survival benefit for adjuvant chemotherapy. (See Principles of Systemic Therapy [MCC-D]).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



TREATMENT OF CLINICAL M1 DISEASE



^j[See Principles of Radiation Therapy \(MCC-B\)](#).

^o[See Principles of Systemic Therapy \(MCC-D\)](#).

^pUnder highly selective circumstances, in the context of multidisciplinary consultation, resection of oligometastasis can be considered.

^q[See Principles of Excision \(MCC-C\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



FOLLOW-UP^a

RECURRENCE

Follow-up visits^f:

- Physical exam including complete skin and complete lymph node exam
 - ▶ Every 3–6 mo for 3 years
 - ▶ Every 6–12 mo thereafter
- Imaging studies as clinically indicatedⁱ
 - ▶ Consider routine imaging for high-risk patients



^aQuantitation of MCPyV oncoprotein antibodies may be considered as part of initial workup; sero-negative patients may have a higher risk of recurrence; in sero-positive patients, a rising titer may be an early indicator of recurrence.

ⁱBrain MRI with contrast and neck/chest/abdomen/pelvis CT with contrast or whole body FDG PET/CT may be useful to identify and quantify regional and distant metastases. Some studies indicate that whole body FDG PET/CT may be preferred in some clinical circumstances. If whole body FDG PET/CT is not available, CT or MRI with contrast may be used.

^fAs immunosuppressed patients are at high risk for recurrence, more frequent follow-up may be indicated. Immunosuppressive treatments should be minimized as clinically feasible.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF PATHOLOGY


- **Pathologist should be experienced in distinguishing MCC from cutaneous simulants and metastatic tumors.**
- **Synoptic reporting is preferred.**
- **Minimal elements to be reported include tumor size (cm), peripheral and deep margin status, lymphovascular invasion, and extracutaneous extension (ie, bone, muscle, fascia, cartilage).**
- **Strongly encourage reporting of these additional clinically relevant factors (compatible with the American Joint Committee on Cancer [AJCC] and the College Of American Pathologists [CAP] recommendations):**
 - ▶ **Depth (Breslow, in mm)**
 - ▶ **Mitotic index (#/mm² preferred, #/HPF [High-power fields], or MIB-1 index)**
 - ▶ **Tumor-infiltrating lymphocytes (not identified, brisk, non-brisk)**
 - ▶ **Tumor growth pattern (nodular or infiltrative)**
 - ▶ **Presence of a second malignancy within the pathologic specimen itself (ie, concurrent squamous cell carcinoma [SCC])**
- **An appropriate immunopanel should preferably include CK20 and thyroid transcription factor-1 (TTF-1). Immunohistochemistry for CK20 and most low-molecular-weight cytokeratin markers is typically positive with a paranuclear “dot-like” pattern. CK7 and TTF-1 (positive in >80% of small cell lung cancers) are typically negative.**
- **For equivocal lesions, consider additional immunostaining with neuroendocrine markers such as chromogranin, synaptophysin, CD56, neuron-specific enolase (NSE), and neurofilament.**
- **SLNB evaluation should preferably include an appropriate immunopanel (ie, CK20 and pancytokeratins [AE1/AE3]) based on the immunostaining pattern of the primary tumor, particularly if H&E sections are negative, as well as tumor burden (% of node), tumor location (eg, subcapsular sinus, parenchyma), and the presence/absence of extracapsular extension.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF RADIATION THERAPY




- Expeditious initiation of adjuvant therapy after surgery is preferred as delay has been associated with worse outcomes.
- All doses are at 2 Gy/d standard fractionation. Bolus is used to achieve adequate skin dose. Wide margins (5 cm) should be used, if possible, around the primary site. If electron beam is used, an energy and prescription isodose should be chosen that will deliver adequate dose to the lateral and deep margins.
- Palliation: A less protracted fractionation schedule may be used in the palliative setting, such as 30 Gy in 10 fractions.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF RADIATION THERAPY



- **Expeditious initiation of adjuvant therapy after surgery is preferred as delay has been associated with worse outcomes.**
- **All doses are at 2 Gy/d standard fractionation. A less protracted fractionation schedule may be used in the palliative setting, such as 30 Gy in 10 fractions.**
- **Irradiation of in-transit lymphatics is often not feasible unless the primary site is in close proximity to the nodal bed.**

¹Lymph node dissection is the recommended initial therapy for clinically evident adenopathy, followed by postoperative RT if indicated.

²Shrinking field technique.

³Consider RT when there is a potential for anatomic (eg, previous WLE), operator, or histologic failure (eg, failure to perform appropriate immunohistochemistry on SLNs) that may lead to a false-negative SLNB.

⁴In the head and neck region, risk of false-negative SLNB is higher due to aberrant lymphatic drainage and frequent presence of multiple SLN basins. If SLNB is unsuccessful, consider irradiating draining nodal basin for subclinical disease.

⁵Microscopic nodal disease (SLN positive) is defined as nodal involvement that is neither clinically palpable nor abnormal by imaging criteria, and microscopically consists of small metastatic foci without extracapsular extension.

⁶Adjuvant RT following lymph node dissection is only indicated for multiple involved nodes and/or the presence of extracapsular extension. Adjuvant RT following LN dissection is generally not indicated for patients with low tumor burden on SLNB or with a single macroscopic clinically detected lymph node without extracapsular extension.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF EXCISION

Goals:

- To obtain histologically negative margins when clinically feasible.
- Surgical margins should be balanced with morbidity of surgery. If appropriate, avoid undue delay in proceeding to radiation therapy.

Surgical Approaches:

- It is recommended, regardless of the surgical approach, that every effort be made to coordinate surgical management such that SLNB is performed prior to definitive excision.¹ Excision options include:
 - ▶ Wide excision with 1- to 2-cm margins to investing fascia of muscle or pericranium when clinically feasible.
 - ▶ Techniques for more exhaustive histologic margin assessment may be considered (Mohs micrographic surgery, modified Mohs micrographic surgery, CCPDMA),^{2,3} provided they do not interfere with SLNB when indicated.

Reconstruction:

- It is recommended that any reconstruction involving extensive undermining or tissue movement be delayed until negative histologic margins are verified and SLNB is performed if indicated.
- If adjuvant radiation therapy is planned, extensive tissue movement should be minimized and closure should be chosen to allow for expeditious initiation of radiation therapy.

¹SLNB is an important staging tool and may contribute to regional control; the impact of SLNB on overall survival is unclear.

²If Mohs micrographic surgery is used, a debulked specimen of the central portion of the tumor should be sent for permanent vertical section microstaging.

³Modified Mohs = Mohs micrographic surgery with additional permanent section final margin assessment; CCPDMA = complete circumferential and peripheral deep margin assessment.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF SYSTEMIC THERAPY¹

Local Disease:

- Adjuvant chemotherapy not recommended

Regional Disease:

- Clinical trial (preferred)
- Adjuvant chemotherapy not routinely recommended as survival benefit has not been demonstrated in available retrospective studies, but could be used on a case-by-case basis if clinical judgement dictates
 - ▶ Cisplatin ± etoposide
 - ▶ Carboplatin ± etoposide

Disseminated Disease:

- Clinical trial (preferred)
- Avelumab²
- Pembrolizumab²
- Nivolumab²
- As clinical judgment dictates for patients with contraindications to checkpoint immunotherapy:
 - ▶ Cisplatin ± etoposide
 - ▶ Carboplatin ± etoposide
 - ▶ Topotecan
 - ▶ (CAV): Cyclophosphamide, doxorubicin (or epirubicin), and vincristine

¹When available and clinically appropriate, enrollment in a clinical trial is recommended. The literature is not directive regarding the specific chemotherapeutic agent(s) offering superior outcomes, but the literature does provide evidence that Merkel cell carcinoma is chemosensitive, although the responses are not durable, and the agents listed above have been used with some success.

²Preliminary data from non-randomized trials in patients with MCC demonstrate that rates of durable response are improved with PD-1/PD-L1 blockade compared with cytotoxic therapy. The safety profiles for checkpoint immunotherapies are significantly different from cytotoxic therapies. Consult prescribing information for recommendations on detection and management of immune-related adverse events associated with checkpoint immunotherapies. Clinician and patient education is critical for safe administration of checkpoint immunotherapies.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2018 Staging Merkel Cell Carcinoma

Staging

American Joint Committee on Cancer (AJCC)
TNM Staging Classification for Merkel Cell Carcinoma
(8th ed., 2016)

Primary Tumor (T)

TX	Primary tumor cannot be assessed (e.g., curetted)
T0	No evidence of primary tumor
Tis	<i>In situ</i> primary tumor
T1	Maximum clinical tumor diameter ≤2 cm
T2	Maximum clinical tumor diameter >2 but ≤5 cm
T3	Maximum clinical tumor diameter >5 cm
T4	Primary tumor invades fascia, muscle, cartilage, or bone

Regional Lymph Nodes (N)

Clinical (N)

NX	Regional lymph nodes cannot be clinically assessed (e.g., previously removed for another reason, or because of body habitus)
N0	No regional lymph node metastasis detected on clinical and/or radiologic examination
N1	Metastasis in regional lymph node(s)
N2	In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis
N3	In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis

The AJCC 8th Edition Cancer Staging System will be implemented on January 1, 2018. For the AJCC 7th Edition Staging Manual, visit www.springer.com.

Pathological (pN)

pNX	Regional lymph nodes cannot be assessed (e.g., previously removed for another reason or not removed for pathological evaluation)
pN0	No regional lymph node metastasis detected on pathological evaluation
pN1	Metastasis in regional lymph node(s)
pN1a(sn)	Clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy
pN1a	Clinically occult regional lymph node metastasis following lymph node dissection
pN1b	Clinically and/or radiologically detected regional lymph node metastasis microscopically confirmed
pN2	In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis
pN3	In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis

Distant Metastasis (M)

Clinical (M)

M0	No distant metastasis detected on clinical and/or radiologic examination
M1	Distant metastasis detected on clinical and/or radiologic examination
M1a	Metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s)
M1b	Metastasis to lung
M1c	Metastasis to all other visceral sites

Pathological (M)

M0	No distant metastasis detected on clinical and/or radiologic examination
pM1	Distant metastasis microscopically confirmed
pM1a	Metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s), microscopically confirmed
pM1b	Metastasis to lung, microscopically confirmed
pM1c	Metastasis to all other distant sites, microscopically confirmed

Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2016) published by Springer Science+Business Media. (For complete information and data supporting the staging tables, visit www.springer.com.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.



Staging continued

American Joint Committee on Cancer (AJCC) TNM Staging Classification for Merkel Cell Carcinoma (8th ed., 2016)

AJCC Prognostic Stage Groups

Clinical (cTNM)

Tis	N0	M0	0
T1	N0	M0	I
T2–3	N0	M0	IIA
T4	N0	M0	IIB
T0–4	N1–3	M0	III
T0–4	Any N	M1	IV

Pathological (pTNM)

Tis	N0	M0	0
T1	N0	M0	I
T2–3	N0	M0	IIA
T4	N0	M0	IIB
T1–4	N1a(sn) or N1a	M0	IIIA
T0	N1b	M0	IIIA
T1–4	N1b–3	M0	IIIB
T0–4	Any N	M1	IV

The AJCC 8th Edition Cancer Staging System will be implemented on January 1, 2018. For the AJCC 7th Edition Staging Manual, [visit www.springer.com](http://www.springer.com).

Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2016) published by Springer Science+Business Media. (For complete information and data supporting the staging tables, visit www.springer.com.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.

Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 12/16/14

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview	MS-2
Diagnosis and Workup	MS-2
Pathology Report.....	MS-2
Imaging.....	MS-3
Staging	MS-3
Treatment	MS-3
Surgery.....	MS-4
Sentinel Lymph Node Biopsy.....	MS-4
Radiation Therapy.....	MS-5
Chemotherapy.....	MS-5
NCCN Recommendations.....	MS-6
Follow-up and Recurrence	MS-6
References	MS-8

Overview

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer along with the regional and distant metastatic rates of thick melanoma.¹ Several large reviews document the development of local recurrence in 25% to 30% of all cases of MCC, 52% to 59% of all cases of regional disease, and 34% to 36% of all cases of distant metastatic disease.²⁻⁴ MCC has a high mortality rate that exceeds that of melanoma. The overall 5-year survival rates range from 30% to 64%.⁵⁻⁷

A history of extensive sun exposure is a major risk factor for MCC. Older Caucasians (65 years or older) are at higher risk for MCC, which tends to occur on the areas of the skin that are exposed to the sun.⁸ MCC is disproportionately more common in immunosuppressed individuals, such as those with organ transplants, lymphoproliferative malignancies (such as chronic lymphocytic leukemia), or HIV infections.¹

In 2008, Feng and colleagues⁹ identified a novel polyomavirus in MCC tumor tissues. This Merkel cell polyomavirus (MCV or MCPyV) is detected in 43% to 100% of patient samples.¹⁰ The role of MCV in the pathogenesis of MCC is under active investigation.¹¹ There is ongoing research on the value of baseline MCV serology to predict outcome and to detect disease recurrence.^{12,13}

The NCCN Non-Melanoma Skin Cancer Panel has developed guidelines outlining treatment of MCC to supplement the squamous cell and basal cell skin cancer guidelines (see [NCCN Guidelines for Basal Cell Skin Cancer and NCCN Guidelines for Squamous Cell Skin Cancer](#)).¹⁴ MCC is a rare tumor; therefore, prospective, statistically significant data are lacking to verify the validity of prognostic features or

treatment outcomes. The panel relied on trends that are documented in smaller, individual studies, in meta-analyses, and in their own collective experiences.

Diagnosis and Workup

The diagnosis of MCC is rarely clinically suspected, as the primary tumor lacks distinguishing characteristic features. Initial workup of a suspicious lesion starts with a complete examination of the skin and lymph nodes followed by biopsy. The histologic diagnosis may also be challenging because MCC is similar to a variety of other widely recognized small round blue cell tumors. The most difficult differentiation is often between primary MCC and metastatic small cell carcinoma of the lung.

Pathology Report

The Principles of Pathology in the algorithm outlined elements that should be included in a pathology report, preferably in synoptic format. The College of American Pathologists (CAP) provides a complete synoptic report protocol for cutaneous MCC.¹⁵ The goals are to: 1) accurately diagnose the condition and distinguish it from cutaneous simulants and metastatic tumors; 2) provide complete pathologic tumor characteristics for staging according to recommended AJCC and CAP guidelines; and 3) standardize pathologic data collection to further understand the critical biological features that impact MCC behavior and prognosis. At a minimum, the report should include tumor size, peripheral and deep margin status, lymphovascular invasion, and extracutaneous extension to the bone, muscle fascia, or cartilage. The prognostic value of histopathologic features of the primary tumor remains uncertain. However, there is an emerging body of literature that suggests that tumor thickness, mitotic rate, tumor growth pattern, tumor-infiltrating lymphocytes (particularly intratumoral CD8+ lymphocytes),

and the presence of a second malignancy such as concurrent squamous cell carcinoma may provide relevant prognostic information with regards to survival and/or sentinel lymph node positivity in MCC.¹⁶⁻²⁰ It is therefore suggested that these features be included in the pathology report whenever possible.

Initial diagnosis of MCC in the primary lesion by hematoxylin and eosin (H&E) staining should be further confirmed by performing immunohistochemical (IHC) staining. An appropriate immunopanel should preferably include cytokeratin 20 (CK-20) and thyroid transcription factor 1 (TTF-1), which often provide the greatest sensitivity and specificity to exclude small cell lung cancer (SCLC).²¹⁻²³ CK-20 is a very sensitive marker for MCC, since it is positive in 89% to 100% of cases. TTF-1 is expressed in 83% to 100% of SCLC but it is consistently absent in MCC. Other IHC markers such as chromogranin A, synaptophysin, neurofilament protein, neuron specific enolase, and CD56 may be used in addition to CK-20 and TTF-1 to exclude other diagnostic considerations.²⁴

Imaging

Additional workup of a patient with MCC may include imaging studies.²⁵ In asymptomatic patients with primary MCC, sentinel lymph node biopsy (SLNB) is considered the most sensitive staging test for the detection of nodal metastases.^{17,18,20} Imaging may be useful in identifying distant metastases as clinically indicated due to the metastatic potential of this tumor. PET/CT scanning is gaining importance in diagnostic imaging of MCC and may be preferred in some instances. CT or MRI may be used if PET/CT is not available. In a review of 102 patients, PET/CT changed the stage and primary treatment of 22% of patients.²⁶ PET also altered the radiation technique or dose for another 15% of patients. Similar results were reported in another review of 97 patients, 16% of whom

were upstaged by baseline PET/CT scans.²⁷ In addition, PET/CT frequently identified bone metastases that were undetected by CT. According to a meta-analysis of 6 studies, the sensitivity and specificity of PET/CT are 90% and 98%, respectively.²⁸

Imaging (CT, MRI, or PET/CT scan) may also be indicated to evaluate for the possibility of a skin metastasis from a noncutaneous carcinoma (eg, small cell carcinoma of the lung), especially in cases where CK-20 is negative.

Staging

In the biomedical literature, the most consistently reported adverse prognostic feature is tumor stage followed by tumor size.^{2,4,29-35} The NCCN staging of MCC parallels the AJCC guidelines and divides presentation into local, regional, and disseminated disease.³⁶ The AJCC staging system is based on an analysis of 5823 cases from the National Cancer Data Base with a median follow-up of 64 months.⁷ An MCC website from Seattle Cancer Care Alliance also has a useful staging table (www.merkelcell.org).

Treatment

After workup, treatment is primarily dependent on accurate histopathologic interpretation and on microstaging of the primary lesion. A multidisciplinary panel is recommended to ensure high-quality coordinated care for patients diagnosed with this rare and challenging disease.³⁷

Surgery is the primary treatment modality for MCC. However, there is some variability among individual clinicians and NCCN Member Institutions regarding the management of patients with MCC due to the absence of prospective clinical trials. Therefore, the MCC guidelines are

suitably broad to reflect all the approaches taken by participating NCCN Member Institutions.

Surgery

Surgery is the mainstay of primary treatment for clinically localized (N0, M0) MCC.³⁸ Because of the high historic risk of local recurrence in MCC, the panel's tenets for surgical excision emphasize complete extirpation of tumor at the time of initial resection to achieve clear surgical margins when clinically feasible. However, this should not be pursued to the degree of significantly delaying any planned adjuvant radiation therapy (RT). An analysis of 3 pooled prospective trials in patients receiving adjuvant RT for high-risk MCC found that pre-radiation margin status had no impact on time to locoregional failure.³⁹

Wide local excision with 1- to 2-cm margins to the investing fascia layer remains the standard surgical technique.³⁸ Mohs surgery, modified Mohs surgery, or complete circumferential peripheral and deep-margin assessment (CCPDMA) may be considered if tissue sparing is critical, such as for facial MCC.^{40,41} Mohs micrographic surgery is superior to conventional surgical excision in high-risk basal cell carcinoma and squamous cell carcinoma. In MCC, it may be used to ensure complete tumor removal and clear margins, while secondarily sparing surrounding healthy tissue.⁴² If Mohs is used, the panel emphasized that a specimen from the central portion of the tumor should be sent for permanent section microstaging.

In all cases, treatment should be coordinated so that SLNB is performed prior to definitive surgery as surgery may alter lymphatic drainage. SLNB is usually performed intraoperatively during wide local excision.

Reconstruction

Reconstruction is usually performed immediately after surgery. As histologic margins may be obscured by extensive undermining or tissue movement, verification of clear margins should precede any major reconstruction. Efforts should also be made to minimize delay to adjuvant radiation, such as by primary closure. If postoperative radiation is planned, significant tissue movement should be avoided as it may obscure the target area.

Sentinel Lymph Node Biopsy

SLNB is very important in the staging and treatment of MCC, although its impact on overall survival has been mixed in literature.⁴³ One review of 161 patients with MCC found that SLNB identified micrometastases in one-third of early-stage patients.⁴⁴ Recurrence occurred in 56% of SLNB-positive and 39% of SLNB-negative patients. Essentially all participating NCCN Member Institutions use the SLNB technique routinely for MCC, as they do for melanoma. The NCCN Panel believes that by identifying patients with positive microscopic nodal disease and then performing full lymph node dissections and/or RT, the care of regional disease in this patient population is maximized. However, it should be noted that compared to the trunk and extremities, SLNB may be less reliable in the head and neck region. The complex and variable drainage pattern of the area can lead to false negativity.⁴⁵ Performing a wide local excision before SLNB may potentially interfere with the accuracy of subsequent SLNB.

IHC analysis has been shown to be effective in detecting more lymph node metastases in patients with MCC and should be included in the SLNB evaluation in addition to H&E sections.^{6,46} CK-20 immunostaining in the pathologic assessment of sentinel lymph nodes removed from MCC patients is a valuable diagnostic adjunct, as it allows accurate identification of micrometastases.^{47,48} Other elements to be detailed are

the tumor burden of each node, location, and the presence or absence of extracapsular extension.

Radiation Therapy

Although the literature on the benefits of RT has been mixed, recent studies are providing increasing support for the use of postoperative radiation in MCC to minimize locoregional recurrence.⁴⁹ According to a meta-analysis comparing surgery alone with surgery plus adjuvant radiation, the use of local adjuvant radiation after complete excision lowered the risk of local and regional recurrences.⁵⁰ Jouary and colleagues⁵¹ conducted the only randomized trial to date in MCC. Patients with stage I disease treated by wide excision and RT to the tumor bed were randomized to adjuvant regional RT or observation. The trial was closed prematurely due to a drop in recruitment attributed to the advent of sentinel node dissection. Analysis of 83 patients showed no overall survival improvement with adjuvant radiation, but a significant decrease in risk of regional recurrence was found compared to the observation group (0% vs. 16.7%). A large retrospective analysis of 1187 cases from the SEER database demonstrated longer overall survival of patients who received adjuvant RT compared to those who did not after surgery (median survival 63 months vs. 45 months; $P = .0002$).⁵² Improvement was most pronounced for patients with tumors larger than 2 cm (median survival 50 months vs. 21 months; $P = .0003$). Another analysis of the SEER database also reported improved overall survival with adjuvant RT, although disease-specific survival was not improved.⁵³ The panel included radiation as a treatment option for all stages of MCC. However, due to the lack of prospective trials with clearly defined patient cohorts and treatment protocols (eg, surgical margins prior to RT, location of radiation field), the recommendations are suitably broad to reflect all the approaches taken by participating NCCN Member Institutions. Adjuvant radiation is commonly performed

within a few weeks after surgery, as delay may lead to negative outcomes. Radiation may also be useful in the palliative setting. Specifications on radiation dosing, as well as for different MCC sites (head and neck vs. extremity and torso), are detailed in the algorithm under *Principles of Radiation Therapy*.

Chemotherapy

There is sparse literature on chemotherapeutic options for MCC.⁵⁴ Most NCCN Member Institutions only use chemotherapy with or without surgery and/or RT for stage IV, distant metastatic disease (M1). A few NCCN Member Institutions suggest considering adjuvant chemotherapy for select cases of clinical (macroscopic) regional (N1b or N2) disease. The most common regimen used for regional disease is cisplatin or carboplatin with or without etoposide. Available data from retrospective studies do not suggest prolonged survival benefit for adjuvant chemotherapy.^{55,56} Data are insufficient to assess whether chemotherapeutic regimens improve either relapse-free or overall survival in MCC patients with distant metastatic disease.^{5,57-61} If it is used, the panel recommends cisplatin or carboplatin with or without etoposide.^{5,62} Topotecan has also been used in some instances (eg, older patients). Cyclophosphamide in combination with doxorubicin and vincristine (CAV) used to be a commonly administered regimen, but it is associated with significant toxicity.⁵⁹ Clinicians should exercise independent medical judgment in choosing the chemotherapeutic regimen. Although the NCCN Panel recognized that MCC is a rare disease that precludes robust randomized studies, enrollment in clinical trials is encouraged whenever available and appropriate.

NCCN Recommendations

Clinical Node-Negative Disease

Wide local excision of the entire lesion with clear surgical margins is preferred, whenever possible. Surgical margins should be balanced with morbidity of surgery. SLNB is offered to patients with clinical N0 disease for accurate nodal staging.

Following surgery, patients may undergo postoperative RT of the primary site or consider observation. Efforts should be made to avoid delay of adjuvant RT if planned. Observation should be limited to patients with small primary lesions (eg, less than 1 cm) that have been widely excised and present with no adverse risk factors such as lymphovascular invasion or immunosuppression.⁶³

Radiation is acceptable as primary therapy in select cases when complete excision is not feasible or refused by the patient.

A positive sentinel lymph node is preferably followed up with a multidisciplinary tumor board consultation. Baseline imaging with CT, MR, or PET/CT should be considered as these may be helpful in detecting regional and distant metastases. PET/CT may be preferred in certain instances. Where available, clinical trial participation is the preferred choice for patients with positive SLNB. Most patients undergo completion lymph node dissection and/or RT to the nodal basin. If SLNB results are negative, observation is appropriate. Patients with profound immunosuppression or who are at high risk may consider RT to the nodal basin. If SLNB is not performed or is unsuccessful, RT to the nodal bed should be considered.

Clinical Node-Positive Disease

A clinical N+ diagnosis should be confirmed by fine-needle aspiration or core biopsy with an appropriate immunopanel.

If initial biopsy results are positive, imaging studies (CT, MRI, or PET/CT) are recommended if not already performed at baseline. If distant metastasis is detected, management should follow the M1 pathway. If no distant metastasis is present, the panel recommends multidisciplinary tumor board consultation and lymph node dissection. RT is recommended following lymph node dissection if extracapsular extension is detected or multiple nodes are involved. Adjuvant chemotherapy may be considered in select cases, although no survival benefit has been reported.

An open biopsy may be considered to confirm a negative initial biopsy. If results remain negative, patients should be managed as clinical N0.

Metastatic Disease

The panel recommends multidisciplinary tumor board consultation for patients with metastatic disease to consider any or a combination of chemotherapy, radiation, and surgery. Full imaging workups are recommended for all patients with clinically proven regional or metastatic disease. In general, the management of patients with distant metastases must be individually tailored. Clinical trial is preferred if available. Chemotherapy and RT will likely be the primary treatment options to consider. Surgery may be beneficial for select patients with oligometastasis. All patients should receive best supportive care. The NCCN Panel encourages participation in clinical trials where available.

Follow-up and Recurrence

The NCCN Panel's recommendations for close clinical follow-up of MCC patients immediately after diagnosis and treatment parallel the recommendations in the literature. The physical examination should include a complete skin and regional lymph node examination every 3 to 6 months for the first two years, then every 6 to 12 months thereafter. The recommended frequency of follow-up visits is purposely broad to



allow for an individualized schedule based on the risk of recurrence, stage of disease, and other factors such as patient anxiety and clinician preference. The panel's recommendations also reflect the fact that the median time to recurrence in patients with MCC is about 8 months, with 90% of the recurrences occurring within 24 months.^{5,6,32} Self-examination of the skin is useful for patients with MCC, because these patients are likely at greater risk for other non-melanoma skin cancers. Imaging studies should be performed as clinically indicated. For high-risk patients, routine imaging should be considered. PET/CT scans may be useful to identify and quantify metastases, especially bone involvement.²⁷

Patients who present with local or regional recurrence should receive individualized treatment. For disseminated recurrence, follow the treatment pathway for metastatic disease.

Discussion
update in
progress

References

1. Becker JC. Merkel cell carcinoma. *Ann Oncol* 2010;21 Suppl 7:vii81-vii85. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20943647>.
2. Akhtar S, Oza KK, Wright J. Merkel cell carcinoma: report of 10 cases and review of the literature. *J Am Acad Dermatol* 2000;43:755-767. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11050578>.
3. Gillenwater AM, Hessel AC, Morrison WH, et al. Merkel cell carcinoma of the head and neck: effect of surgical excision and radiation on recurrence and survival. *Arch Otolaryngol Head Neck Surg* 2001;127:149-154. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11177031>.
4. Medina-Franco H, Urist MM, Fiveash J, et al. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. *Ann Surg Oncol* 2001;8:204-208. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11314935>.
5. Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. *J Clin Oncol* 2005;23:2300-2309. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15800320>.
6. Bichakjian CK, Lowe L, Lao CD, et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. *Cancer* 2007;110:1-12. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17520670>.
7. Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. *J Am Acad Dermatol* 2010;63:751-761. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20646783>.
8. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. *J Am Acad Dermatol* 2003;49:832-841. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14576661>.
9. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. *Science* 2008;319:1096-1100. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18202256>.
10. Rollison DE, Giuliano AR, Becker JC. New virus associated with merkel cell carcinoma development. *J Natl Compr Canc Netw* 2010;8:874-880. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20870633>.
11. Amber K, McLeod MP, Nouri K. The Merkel cell polyomavirus and its involvement in Merkel cell carcinoma. *Dermatol Surg* 2013;39:232-238. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23387356>.
12. Paulson KG, Carter JJ, Johnson LG, et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. *Cancer Res* 2010;70:8388-8397. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20959478>.
13. Touze A, Le Bidre E, Laude H, et al. High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. *J Clin Oncol* 2011;29:1612-1619. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21422439>.
14. Miller SJ, Alam M, Andersen J, et al. Merkel cell carcinoma. *J Natl Compr Canc Netw* 2006;4:704-712. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16884672>.
15. Rao P, Balzer BL, Lemos BD, et al. Protocol for the examination of specimens from patients with merkel cell carcinoma of the skin. *Arch Pathol Lab Med* 2010;134:341-344. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20196661>.
16. Andea AA, Coit DG, Amin B, Busam KJ. Merkel cell carcinoma: histologic features and prognosis. *Cancer* 2008;113:2549-2558. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18798233>.

17. Fields RC, Busam KJ, Chou JF, et al. Recurrence and Survival in Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma: Analysis of 153 Patients from a Single Institution. *Ann Surg Oncol* 2011. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21431988>.
18. Schwartz JL, Griffith KA, Lowe L, et al. Features predicting sentinel lymph node positivity in Merkel cell carcinoma. *J Clin Oncol* 2011;29:1036-1041. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21300936>.
19. Paulson KG, Iyer JG, Tegeder AR, et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. *J Clin Oncol* 2011;29:1539-1546. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21422430>.
20. Fields RC, Busam KJ, Chou JF, et al. Five hundred patients with merkel cell carcinoma evaluated at a single institution. *Ann Surg* 2011;254:465-475. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21865945>.
21. Cheuk W, Kwan MY, Suster S, Chan JK. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. *Arch Pathol Lab Med* 2001;125:228-231. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11175640>.
22. Hanly AJ, Elgart GW, Jorda M, et al. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung. *J Cutan Pathol* 2000;27:118-120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10728812>.
23. Scott MP, Helm KF. Cytokeratin 20: a marker for diagnosing Merkel cell carcinoma. *Am J Dermatopathol* 1999;21:16-20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10027519>.
24. Gruber SB, Wilson LD. Merkel cell carcinoma. *Cutaneous Oncology: pathophysiology, diagnosis, and management*. Malden, MA: Blackwell Science; 1998:710-721.
25. Enzenhofer E, Ubl P, Czerny C, Erovic BM. Imaging in patients with merkel cell carcinoma. *J Skin Cancer* 2013;2013:973123. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23476783>.
26. Siva S, Byrne K, Seel M, et al. 18F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in the Staging of Merkel Cell Carcinoma: A 15-Year Institutional Experience. *J Nucl Med* 2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23753187>.
27. Hawryluk EB, O'Regan KN, Sheehy N, et al. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. *J Am Acad Dermatol* 2013;68:592-599. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23127473>.
28. Treglia G, Dabbagh Kakhki VR, Giovanella L, Sadeghi R. Diagnostic Performance of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Merkel Cell Carcinoma: A Systematic Review and Meta-Analysis. *Am J Clin Dermatol* 2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23959776>.
29. Allen PJ, Zhang ZF, Coit DG. Surgical management of Merkel cell carcinoma. *Ann Surg* 1999;229:97-105. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9923806>.
30. Haag ML, Glass LF, Fenske NA. Merkel cell carcinoma. Diagnosis and treatment. *Dermatol Surg* 1995;21:669-683. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7633811>.
31. Kokoska ER, Kokoska MS, Collins BT, et al. Early aggressive treatment for Merkel cell carcinoma improves outcome. *Am J Surg* 1997;174:688-693. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9409598>.

32. Ott MJ, Tanabe KK, Gadd MA, et al. Multimodality management of Merkel cell carcinoma. *Arch Surg* 1999;134:388-392; discussion 392-383. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10199311>.
33. Pitale M, Sessions RB, Husain S. An analysis of prognostic factors in cutaneous neuroendocrine carcinoma. *Laryngoscope* 1992;102:244-249. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1545650>.
34. Ratner D, Nelson BR, Brown MD, Johnson TM. Merkel cell carcinoma. *J Am Acad Dermatol* 1993;29:143-156. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8335732>.
35. Skelton HG, Smith KJ, Hitchcock CL, et al. Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. *J Am Acad Dermatol* 1997;37:734-739. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9366819>.
36. Merkel Cell Carcinoma. In: Edge SB, Carducci M, Byrd DR, eds. *AJCC Cancer Staging Manual* (ed 7). New York: Springer-Verlag New York, LLC; 2009.
37. Schneider S, Thurnher D, Erovic BM. Merkel cell carcinoma: interdisciplinary management of a rare disease. *J Skin Cancer* 2013;2013:189342. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23401779>.
38. Tai P. A practical update of surgical management of merkel cell carcinoma of the skin. *ISRN Surg* 2013;2013:850797. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23431473>.
39. Finnigan R, Hruby G, Wratten C, et al. The impact of preradiation residual disease volume on time to locoregional failure in cutaneous Merkel cell carcinoma--a TROG substudy. *Int J Radiat Oncol Biol Phys* 2013;86:91-95. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23290441>.
40. Boyer JD, Zitelli JA, Brodland DG, D'Angelo G. Local control of primary Merkel cell carcinoma: review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiation. *J Am Acad Dermatol* 2002;47:885-892. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12451374>.
41. O'Connor WJ, Roenigk RK, Brodland DG. Merkel cell carcinoma. Comparison of Mohs micrographic surgery and wide excision in eighty-six patients. *Dermatol Surg* 1997;23:929-933. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9357504>.
42. Pennington BE, Leffell DJ. Mohs micrographic surgery: established uses and emerging trends. *Oncology (Williston Park)* 2005;19:1165-1171; discussion 1171-1162, 1175. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16255133>.
43. Gupta SG, Wang LC, Penas PF, et al. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. *Arch Dermatol* 2006;142:685-690. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16785370>.
44. Santamaria-Barria JA, Boland GM, Yeap BY, et al. Merkel cell carcinoma: 30-year experience from a single institution. *Ann Surg Oncol* 2013;20:1365-1373. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23208132>.
45. Willis AI, Ridge JA. Discordant lymphatic drainage patterns revealed by serial lymphoscintigraphy in cutaneous head and neck malignancies. *Head Neck* 2007;29:979-985. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17525953>.
46. Allen PJ, Busam K, Hill AD, et al. Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel cell carcinoma. *Cancer* 2001;92:1650-1655. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11745244>.
47. Su LD, Lowe L, Bradford CR, et al. Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in

- sentinel lymph nodes. *J Am Acad Dermatol* 2002;46:661-666. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12004304>.
48. Schmalbach CE, Lowe L, Teknos TN, et al. Reliability of sentinel lymph node biopsy for regional staging of head and neck Merkel cell carcinoma. *Arch Otolaryngol Head Neck Surg* 2005;131:610-614. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16027284>.
49. Rush Z, Fields RC, Lee N, Brownell I. Radiation therapy in the management of Merkel cell carcinoma: current perspectives. *Expert Rev Dermatol* 2011;6:395-404. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23565121>.
50. Lewis KG, Weinstock MA, Weaver AL, Otley CC. Adjuvant local irradiation for Merkel cell carcinoma. *Arch Dermatol* 2006;142:693-700. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16785371>.
51. Jouary T, Leyral C, Dreno B, et al. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. *Ann Oncol* 2012;23:1074-1080. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21750118>.
52. Mojica P, Smith D, Ellenhorn JD. Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. *J Clin Oncol* 2007;25:1043-1047. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17369567>.
53. Kim JA, Choi AH. Effect of radiation therapy on survival in patients with resected Merkel cell carcinoma: a propensity score surveillance, epidemiology, and end results database analysis. *JAMA Dermatol* 2013;149:831-838. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23864085>.
54. Desch L, Kunstfeld R. Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. *J Skin Cancer* 2013;2013:327150. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23476782>.
55. Garneski KM, Nghiem P. Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. *J Am Acad Dermatol* 2007;57:166-169. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17482714>.
56. Tai P. Merkel cell cancer: update on biology and treatment. *Curr Opin Oncol* 2008;20:196-200. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18300770>.
57. Poulsen MG, Rischin D, Porter I, et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? *Int J Radiat Oncol Biol Phys* 2006;64:114-119. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16125873>.
58. Poulsen M, Rischin D, Walpole E, et al. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07. *J Clin Oncol* 2003;21:4371-4376. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14645427>.
59. Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. *J Clin Oncol* 2000;18:2493-2499. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10856110>.
60. Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. *Cancer* 1999;85:2589-2595. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10375107>.
61. McAfee WJ, Morris CG, Mendenhall CM, et al. Merkel cell carcinoma: treatment and outcomes. *Cancer* 2005;104:1761-1764. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16136596>.
62. Pectasides D, Pectasides M, Psyrris A, et al. Cisplatin-based chemotherapy for merkel cell carcinoma of the skin. *Cancer Invest* 2006;24:780-785. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17162559>.

63. Paulson KG, Iyer JG, Blom A, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. *J Invest Dermatol* 2013;133:642-646. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23190897>.

